Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. | Respiratory Research BioMed Central Research Open Access Budesonide formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol ED Bateman 1 L Fairall1 DM Lombardi2 and R English1 Address University of Cape Town Lung Institute Cape Town South Africa and 2Hospital Municipal de Rehabilitación Respiratoria María Ferrer Buenos Aires Argentina Email ED Bateman - ebateman@ L Fairall - lfairall@ DM Lombardi - ebateman@ R English - renglish@ Corresponding author Published 24 January 2006 Received 01 September 2005 Respiratory Research 2006 7 13 doi l465-992l-7-l3 Accepted 24 January 2006 This article is available from http content 7 l l 3 2006 Bateman et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background To compare the efficacy and safety of budesonide formoterol Symbicort with formoterol Oxis in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting P2-agonist therapy. Methods In a 3 hour randomized double-blind study a total of 115 patients with acute asthma mean FEVl 40 of predicted normal and a refractory response to salbutamol mean reversibility 2 of predicted normal after inhalation of 400 pg were randomized to receive either budesonide formoterol 320 9 pg 2 inhalations at t -5 minutes and 2 inhalations at 0 minutes total dose 1280 36 pg or formoterol 9 pg 2 inhalations at t -5 minutes and 2 inhalations at 0 minutes total dose 36 pg . The primary efficacy variable was the average FEV 1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1
